NCT00243529View on ClinicalTrials.gov

Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

February 28, 2009

Conditions
Melanoma Stage III or IV
Interventions
BIOLOGICAL

autologous dendritic cell vaccine

Trial Locations (1)

6500 HB

Radboud University Nijmegen Medical Center, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER

collaborator

Dutch Cancer Society

OTHER

NCT00243529 - Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients | Biotech Hunter | Biotech Hunter